Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Lymphoblastic Leukemia With Failed Remission | Biological: CAR T-cell therapy | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients With Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia |
Actual Study Start Date : | December 1, 2015 |
Estimated Primary Completion Date : | December 31, 2020 |
Estimated Study Completion Date : | December 31, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: CAR T-cell therapy
Patients enrolled will receive infusion of CD19-targeting CAR T-cells
|
Biological: CAR T-cell therapy
Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
|
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jia Chen, M.D., Ph.D. | +86 512 67781856 | drchenjia@163.com | |
Contact: Xiang Zhang, M.D. | +86 512 67781856 | lcsy2013@sina.com |
China, Jiangsu | |
The Fisrt Affiliated Hospital of Soochow University | Recruiting |
Suzhou, Jiangsu, China, 215006 | |
Contact: Depei Wu, M.D., Ph.D. +86 512 6778 1856 wudepei@medmail.com.cn | |
Contact: Jia Chen, M.D. +86 512 6778 1856 chenjia@suda.edu.cn | |
Principal Investigator: Depei Wu, M.D., Ph.D. | |
Sub-Investigator: Jia Chen, M.D. | |
Sub-Investigator: Aining Sun, M.D., Ph.D. | |
Sub-Investigator: Huiying Qiu, M.D., Ph.D. | |
Sub-Investigator: Xiaowen Tang, M.D., Ph.D. | |
Sub-Investigator: Yue Han, M.D., Ph.D. | |
Sub-Investigator: Zhengming Jin, M.D. | |
Sub-Investigator: Chengcheng Fu, M.D., Ph.D. | |
Sub-Investigator: Feng Chen, M.D., Ph.D. | |
Sub-Investigator: Xiao Ma, M.D., Ph.D. | |
Sub-Investigator: Suning Chen, M.D., Ph.D. | |
Sub-Investigator: Xiang Zhang, M.D. |
Principal Investigator: | Depei Wu, M.D., Ph.D. | The First Affiliated Hospital of Soochow University |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | April 15, 2019 | ||||||||
First Posted Date ICMJE | April 18, 2019 | ||||||||
Last Update Posted Date | July 1, 2020 | ||||||||
Actual Study Start Date ICMJE | December 1, 2015 | ||||||||
Estimated Primary Completion Date | December 31, 2020 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | CAR-T Cell Therapy Targeting to CD19 for R/R ALL | ||||||||
Official Title ICMJE | CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients With Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia | ||||||||
Brief Summary | Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of Differentiation Antigen 19 (CD19) has been proved as a potent approach to attain remission in B-cell R/R patients. Therefore, the investigators conduct a trial to evaluate the the efficacy and safety of locally producing CAR T cells targeting CD19, and to analyze the outcome of enrolled B-cell ALL patients with active disease or persistent residual disease. | ||||||||
Detailed Description | Not Provided | ||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 1 Phase 2 |
||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||||
Condition ICMJE | Acute Lymphoblastic Leukemia With Failed Remission | ||||||||
Intervention ICMJE | Biological: CAR T-cell therapy
Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
|
||||||||
Study Arms ICMJE | Experimental: CAR T-cell therapy
Patients enrolled will receive infusion of CD19-targeting CAR T-cells
Intervention: Biological: CAR T-cell therapy
|
||||||||
Publications * |
|
||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
50 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | December 31, 2023 | ||||||||
Estimated Primary Completion Date | December 31, 2020 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | Child, Adult, Older Adult | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | China | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT03919240 | ||||||||
Other Study ID Numbers ICMJE | SZ4601 | ||||||||
Has Data Monitoring Committee | No | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||||
Responsible Party | The First Affiliated Hospital of Soochow University | ||||||||
Study Sponsor ICMJE | The First Affiliated Hospital of Soochow University | ||||||||
Collaborators ICMJE | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | The First Affiliated Hospital of Soochow University | ||||||||
Verification Date | April 2019 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |